Compare Amgen, Inc. (AMGN) vs DigitalOcean Holdings Inc (DOCN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs DigitalOcean Holdings Inc — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while DigitalOcean Holdings Inc trades at $128.25 (market cap $13.62B). The key difference: Amgen, Inc. is far larger — about 14.4× DigitalOcean Holdings Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while DigitalOcean Holdings Inc pays none. Which is the better fit depends on your goals.
| AMGN | DOCN | |
|---|---|---|
Market Cap | $196.12B | $13.62B |
Sector | Health | Technology |
52-Week High | $388.16 | $181.29 |
52-Week Low | $271.18 | $25.74 |
Enterprise Value | $241.41B | $14.18B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
DigitalOcean (DOCN) trades at $130.49, down 7.38% over the past 24 hours, amid a bearish technical signal. The company reported strong Q1 2026 earnings of $0.44 per share, beating expectations, and anticipates record Q2 2026 results with remaining performance obligations exceeding $800 million. Revenue grew to $901.43 million in 2025, with a net income margin of 24.97%, though valuation ratios remain elevated with a P/E of 57.23. Analyst consensus is bullish with a $174.80 price target.
Outlook remains positive due to accelerating AI-driven cloud demand and strong execution, but risks include high valuation multiples, negative shareholder equity, and competitive pressure from hyperscalers. The stock offers growth potential if AI adoption continues, yet investors should monitor debt levels and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →
